来曲唑联合替西罗莫司作为一线内分泌治疗绝经后晚期乳腺癌的随机Ⅲ期安慰剂对照研究  

Randomized Phase Ⅲ Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer

作　　者：刘健[1] 黄伟炜[1] 钱学珂[2,3] 

机构地区：[1]福建省肿瘤医院乳腺内科,福州350014 [2]汕头大学医学院,广东汕头515031 [3]广东省人民医院肿瘤中心,广东省医学科学院,广州510080

出　　处：《循证医学》2013年第3期135-137,共3页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Wolff AC,Lazar AA,Bondarenko I,et al.Randomized phase Ⅲ placebo-controlled trial of Letrozole plus oral Temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J].J Clin Oncol,2013,31（2）：195-202.2证据水平1a。<正>1文献来源Wolff AC,Lazar AA,Bondarenko I,et al.Randomized phase Ⅲ placebo-controlled trial of Letrozole plus oral Temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J].J Clin Oncol,2013,31(2):195-202.2证据水平1a。

关 键 词：转移性乳腺癌 替西罗莫司 临床试验 Ⅲ期 

分 类 号：R737.9[医药卫生—肿瘤]